+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tyrosine Kinase Inhibitors: Global Market Outlook

  • PDF Icon

    Report

  • 75 Pages
  • November 2023
  • Region: Global
  • BCC Research
  • ID: 5910676
Description Jump to:

Report Scope

In this report, the market has been segmented based on type, application and geography. The report provides an overview of the global tyrosine kinase inhibitor market and analyzes market trends. Using 2022 as the base year, the report provides estimated market data for the forecast period of 2023 through 2028. Market values have been estimated based on the total revenue of tyrosine kinase inhibitor product providers.

The report covers the market for tyrosine kinase inhibitors with regard to the user base across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. The report estimates the global market for tyrosine kinase inhibitors in 2022 and provides projections for the expected market size through 2028. The scope of the study includes tyrosine kinase inhibitor drugs that are already available in the market as well as future prospects.

Report Includes

  • An overview of the global market for tyrosine kinase inhibitors
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Definition of tyrosine kinase inhibitors and their characteristics, and coverage of the market’s dynamics, specifically drivers, inhibitors and opportunities
  • Discussions of novel tyrosine kinase inhibitors and their utility in the human trials
  • Examination of the technologies and methods used for the creation of novel targets and their therapeutic approaches
  • Discussions of market challenges and how to overcome them if the market is to reach its commercialization potential, pipeline drugs and relevant patents
  • Information on recent mergers and acquisitions, collaborations, partnerships and product introductions
  • Profiles of major players in the market

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown
Chapter 2 Summary and Highlights
  • Market Outlook
  • Market Summary
Chapter 3 Market Overview
  • Kinase Inhibitors
  • Types of Kinase Inhibitors
  • Tyrosine Kinase Inhibitors
  • Regulatory Scenario
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
Chapter 4 Market Breakdown by Type and Application
  • Market for Tyrosine Kinase Inhibitors, by Type
  • Receptor Tyrosine Kinase Inhibitors
  • Non-receptor Tyrosine Kinase Inhibitors
  • Market for Tyrosine Kinase Inhibitors, by Application
  • Lung Cancer
  • Chronic Myelogenous Leukemia (CML)
  • Others
Chapter 5 Market Breakdown by Region
  • Global Market for Tyrosine Kinase Inhibitors, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 6 ESG Development
  • Introduction to ESG
  • The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
  • Pharma End User Sustainability in the Industry
  • Case Study
  • Publisher's Viewpoint
Chapter 7 Industry Structure
  • Ranking of Top Companies
  • Pipeline Analysis
  • Patent Analysis
  • Emerging Trends
Chapter 8 Company Profiles
  • Astrazeneca
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis Ag
  • Pfizer Inc.
List of Tables
Summary Table: Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 1: Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
Table 2: Types of Receptor Tyrosine Kinase Inhibitors
Table 3: Types of Non-receptor Tyrosine Kinase Inhibitors
Table 4: FDA-approved Kinase Inhibitors, 2001-2021
Table 5: FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
Table 6: EMA-approved Kinase Inhibitors, 2001-2020
Table 7: Patent Expiration Dates of Tyrosine Kinase Inhibitors
Table 8: Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 9: Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 10: Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 11: Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
Table 12: Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 13: Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
Table 14: Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
Table 15: Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
Table 16: Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 17: North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 18: North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 19: North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 20: European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 21: European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 22: European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 23: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 24: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 25: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 26: Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 27: Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 28: Key Focus Areas in ESG Metrics
Table 29: ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
Table 30: Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
Table 31: Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
Table 32: Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
Table 33: AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 34: Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 35: Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 36: Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 37: Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 38: F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 39: Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 40: Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 41: Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
List of Figures
Summary Figure A: Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Summary Figure B: Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
Figure 1: Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
Figure 2: Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
Figure 3: National Cancer Institute Research Funding, 2012-2019
Figure 4: Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
Figure 5: Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
Figure 6: Global Mrket for Tyrosine Kinase Inhibitors, by Region
Figure 7: Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Figure 8: Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
Figure 9: How a Strong ESG Proposition Benefits Businesses
Figure 10: The 10 Business Sustainability Trends Identified for 2022
Figure 11: ESG Adoption Level Across All Industries, 2021 and 2022
Figure 12: Key Sustainable Practices Being Implemented in Research Laboratories
Figure 13: ESG Commitments of Pfizer
Figure 14: Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
Figure 15: Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
Figure 16: Number of Patents Filed, Granted and Published, 2018-March 2023
Figure 17: Timeline of Kinase Inhibitors, Since 2001

Executive Summary

The goals of this study are to describe the current market scenario for tyrosine kinase inhibitors and to assess the market’s growth over the period from 2021 through the end of 2028. The study aims to estimate the size of the tyrosine kinase inhibitor market at global and regional levels and to explore market dynamics such as drivers, restraints, opportunities, and trends that impact market growth. Types and applications of tyrosine kinase inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and provides a summary of patents.

Reasons for Doing This Study

Extensive research in the field of tyrosine kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of tyrosine kinase inhibitors in their productions and processes. This has led to a steady market for these substances.

Companies Mentioned

  • Astrazeneca
  • Bayer Ag
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis Ag
  • Pfizer Inc.

Related Topics

Related Reports

Tyrosine Kinase Inhibitors Global Market Report 2024 - Product Image

Tyrosine Kinase Inhibitors Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Tyrosine Kinase Inhibitor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Tyrosine Kinase Inhibitor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 89 Pages
  • Global
From
Global Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Forecast 2024-2030 - Product Image

Global Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Tyrosine Kinase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Tyrosine Kinase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Tyrosine Kinase Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Tyrosine Kinase Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From

About the Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors (TKIs) are a class of pharmaceuticals that target tyrosine kinase enzymes, which are involved in the activation of signal transduction pathways that ultimately lead to cell division and proliferation. The dysregulation of tyrosine kinases is a common feature in the pathogenesis of various types of cancer, leading to unchecked cell growth and tumor development. TKIs are therefore an important class of anticancer agents that have reshaped the drug discovery landscape, especially in the treatment of cancers with identifiable molecular targets. In the realm of drug discovery, the market for TKIs has matured with the approval of numerous agents that cover a wide spectrum of targets. Research and innovation focus on improving the efficacy and reducing the side effects, which can include kinome non-selectivity leading to off-target effects. Moreover, the emergence of resistance to first-generation TKIs has spurred the development of second- and third-generation inhibitors that aim to overcome resistance by binding to the kinase domain of mutant enzymes. Several companies are prominent players in the TKI market, frequently associated with pioneering research and the introduction of novel therapeutics. Key names include Novartis, Pfizer, Roche, AstraZeneca, and Bristol Myers Squibb. These companies not only invest heavily in research and development of TKIs but also in the strategic acquisition of smaller biotech firms, partnerships, and collaborations to expand their portfolios and address the diverse needs of patients with cancer. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.